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Anti-angiogenesis
DocetaxelAbstract Introduction: The LUME-Lung 1 trial (NCT00805194; Study 1199.13) demon-
strated a signiﬁcant overall survival (OS) advantage for nintedanib plus docetaxel compared
with placebo plus docetaxel as second-line therapy for patients with advanced non-small cell3, Italy.
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Non-small cell lung
cancer
Quality of lifelung cancer (NSCLC) and adenocarcinoma histology. Patient-reported outcomes (PROs) for
symptoms and health-related quality of life (QoL) are reported here.
Methods: PROs were assessed at screening, on Day 1 of each 21-day treatment cycle, at the
end of active treatment, and at the ﬁrst follow-up visit. PRO instruments were the European
Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30 and
Lung Cancer-13 supplement, and the EuroQol disease-generic questionnaire (EQ-5D and
EQ-VAS). Analyses of PRO items for lung cancer-speciﬁc symptoms of cough, dyspnoea
and pain were prespeciﬁed.
Results: Rates of questionnaire completion were high. There was no signiﬁcant difference in
time to deterioration of global health status/QoL, or symptoms of cough, dyspnoea or pain,
between the treatment groups for both the overall study population and the adenocarcinoma
population. Time to deterioration of some gastrointestinal events was shorter with nintedanib
versus placebo. Longitudinal analysis for the adenocarcinoma population showed comparable
changes between the groups in symptom scores over time, with numerical differences in favour
of nintedanib for cough and pain scales, and signiﬁcant reductions in some pain items with
nintedanib versus placebo. There was no statistically signiﬁcant difference in EQ-5D or EQ-
VAS between the groups.
Conclusion: The signiﬁcant OS beneﬁt observed with the addition of nintedanib to docetaxel
therapy was achieved with no detrimental effect on patient self-reported QoL.
 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
The number of approved second-line treatment
options for non-small cell lung cancer (NSCLC) remains
limited [1], and some options are restricted to patients
with tumours of a speciﬁc histology or molecular proﬁle
[2,3]. Newer agents—such as crizotinib, and where avail-
able, afatinib, ceritinib and geﬁtinib—are only indicated
for those patients with oncogene-dependent tumours [4–
7]. Currently approved oncogene-independent options
include the cytotoxics docetaxel and pemetrexed, but
the survival beneﬁt associated with these two agents is
modest [8,9], and pemetrexed is limited to patients with
non-squamous histology [10]. Erlotinib is also indicated
as second-line therapy irrespective of epidermal growth
factor receptor (EGFR) mutational status [11].
Thus there remains a need for additional eﬀective,
well-tolerated second-line treatment options with wide
application for relapsed/refractory NSCLC. Anti-angio-
genic agents have been intensely investigated as poten-
tial new treatment options. Angiogenesis is critical for
the growth, progression and metastasis of many solid
tumour types, and so it represents a fundamental target
for cancer therapy [12,13]. Yet several clinical trials in
NSCLC with diﬀerent anti-angiogenic tyrosine kinase
inhibitors have failed to show an overall survival (OS)
beneﬁt [14]. To date, ﬁrst-line bevacizumab remains
the only approved anti-angiogenic treatment in the ther-
apeutic armamentarium for advanced NSCLC.
Nintedanib (formerly called BIBF 1120) is a novel,
potent, oral, small-molecule angiokinase inhibitor that
targets three receptor classes involved in angiogenesis:
vascular endothelial growth factor receptors (VEGFR)
1–3, platelet-derived growth factor receptors (PDGFR)
a/b and ﬁbroblast growth factor receptors (FGFR)[15]. In a recent large-scale, Phase III, randomised trial
(LUME-Lung 1; NCT00805194; Study 1199.13), sec-
ond-line treatment with nintedanib plus docetaxel signif-
icantly improved progression-free survival (PFS) versus
placebo plus docetaxel (primary end-point) in the over-
all population of patients with advanced NSCLC (med-
ian PFS 3.4 versus 2.7 months [hazard ratio [HR] 0.79,
95% conﬁdence interval [CI]: 0.68–0.92, p = 0.0019])
and in prespeciﬁed populations of patients with adeno-
carcinoma histology (HR 0.77, 95% CI: 0.62–0.96,
p = 00193) and with adenocarcinoma histology and
poor prognosis (deﬁned as progression within 9 months
of starting prior ﬁrst-line therapy) (median PFS 3.6 ver-
sus 1.5 months [HR 0.63, 95% CI: 0.48–0.83,
p = 00008]) [16]. In the hierarchical analysis, nintedanib
plus docetaxel also signiﬁcantly improved OS versus pla-
cebo plus docetaxel (secondary end-point) in the popu-
lation with adenocarcinoma histology and poor
prognosis (median OS 10.9 versus 7.9 months [HR
0.75, 95% CI: 0.60–0.92; p = 0.0073]) and the adenocar-
cinoma population (median OS 12.6 versus 10.3 months
[HR 0.83, 95% CI: 0.70–0.99; p = 0.0359]), but not in the
overall population [16].
The extension of OS with nintedanib in the LUME-
Lung 1 trial is notable because no study in the preced-
ing decade had shown an OS beneﬁt with second-line
treatment of advanced NSCLC. However, minimising
adverse events and maintaining patient quality of life
(QoL) are also important goals in the second-line set-
ting, where the scope for extension of survival is in
any case limited [17–19]. The LUME-Lung 1 study
used patient-reported outcomes (PROs) as secondary
end-points to assess patients’ subjective perception of
their symptom burden and health-related QoL to sup-
plement the objective measures of eﬃcacy and safety.
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here.2. Patients and methods
2.1. Study design
LUME-Lung 1 was a randomised, placebo-con-
trolled Phase III trial conducted at 211 centres across
27 countries [16]. Eligible patients were adults with con-
ﬁrmed stage III/IV (according to the American Joint
Committee on Cancers) recurrent NSCLC (all histolo-
gies) who had received one previous chemotherapy reg-
imen and had an Eastern Cooperative Oncology Group
(ECOG) performance status of 0 or 1. Patients were ran-
domised (1:1) to receive docetaxel (75 mg/m2 on Day 1)
plus nintedanib (200 mg twice daily on Days 2–21) or
docetaxel plus placebo in a 21-day treatment cycle. Ran-
domisation was stratiﬁed by ECOG performance status
(0 versus 1), previous bevacizumab treatment (yes versus
no), histology (squamous versus non-squamous) and the
presence of brain metastases (yes versus no). Full details
of the study design and methodology have been reported
previously [16].2.2. Patient-reported outcome measures
PROs were assessed at the screening visit, on Day 1
of each 21-day treatment cycle, at the end of active treat-
ment (EOT) and at the ﬁrst follow-up visit. The ques-
tionnaires were completed by patients before seeing
the investigator, and before they were provided with
any new information about their disease status, to avoid
inﬂuencing responses.
PRO instruments consisted of the 30-item European
Organisation for Research and Treatment of Cancer
(EORTC) Core Quality of Life Questionnaire (QLQ-
C30) [20]; its 13-item, lung cancer-speciﬁc supplement
(QLQ-LC13) [21]; and the EuroQol disease-generic
questionnaire, comprising the EQ-5D overall utility
and EQ-visual analogue scale (VAS) [22]. EQ-5D utility
scores were calculated for each subject at each visit from
the ﬁve-item scores using United Kingdom (UK) or
Belgium data preference weightings [23].
The QLQ-C30 incorporates both multi-items scales
and single-item measures, which include one global
health status/QoL scale, ﬁve functional scales, three
symptoms scales and six single items to assess dyspnoea,
insomnia, appetite loss, constipation, diarrhoea and
ﬁnancial diﬃculties [20]. The QLQ-LC13 incorporates
one multi-item scale to assess dyspnoea, and a series
of single items to assess pain, coughing, sore mouth,
dysphagia, peripheral neuropathy, alopecia and
haemoptysis [21]. The analysis plan included evaluation
of the eﬀects of study treatment on prespeciﬁed lung
cancer-speciﬁc symptoms of interest, which were cough(Question Q1 on the QLQ-LC13); dyspnoea (composite
of Q3–5 on the QLQ-LC13); and pain (composite of Q9
and Q19 on the QLQ-C30).2.3. Scoring of the scales/items
The EORTC questionnaire scales/items followed the
EORTC scoring algorithm [24]. To aid interpretation,
a linear transformation was applied to standardise the
raw score for each scale/item to a range from 0 to 100.
For the global health status/QoL scale and functional
scales, a value of 100 was equivalent to the best possible
score and 0 to the worst possible score. For the symp-
tom scales and symptom items, 100 was equivalent to
the highest burden of symptoms and 0 to the lowest bur-
den. Completed questionnaires with missing data were
handled in line with EORTC guidelines, including the
exception for the dyspnoea composite for which all three
responses were required for an individual’s score to be
used [24].2.4. Statistical analyses
Analyses were performed for adenocarcinoma
patients with a time since start of ﬁrst-line therapy to
randomisation into this study <9 months, for the popu-
lation of patients with adenocarcinoma histology, and
the overall population (all histologies) in a hierarchical
order, as prespeciﬁed for the analysis of OS [16].
Time to deterioration (TTD) in PROs was measured
from randomisation to ﬁrst appearance of a minimal
clinically important diﬀerence in the score, deﬁned as
P10-point change lower (for global health status/QoL
and functional scales) or higher (for symptom scales
and items) [25]. TTD was analysed using a log-rank test
stratiﬁed by the four stratiﬁcation factors. A stratiﬁed
Cox proportional hazards model was used to estimate
the HRs and CIs of TTD. Patients without documented
PRO item deterioration were censored at the time of the
patient’s last PRO assessment.
Changes in PROs over the duration of the median
follow-up period were assessed using longitudinal mod-
els. These were mixed-eﬀects growth curve models with
the average proﬁle over time for each PRO end-point
described using a piecewise linear model. A mean score
per patient for each PRO was calculated from the area
under the estimated growth curve (AUC) up to the med-
ian follow-up time. Treatment group mean scores were
then derived from the patient scores. The treatment
eﬀect was estimated as the average diﬀerence between
the treatment group scores, together with the 95% CIs
and associated p-values based on a t-statistic with
degrees of freedom calculated using the Kenward–Roger
method [26].
Potential correlation between missing PRO data and
outcome variables was assessed using Kendall’s tau
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introduce bias was assessed in sensitivity analyses using
joint models, which consisted of the longitudinal model
and a time-to-event variable representing the withdrawal
process. Time to last PRO assessment was used as the
time-to-event variable, and it was assumed to have a
Weibull distribution.
3. Results
3.1. Patients
A total of 1773 patients were screened, of whom 1314
were eligible and randomised to study treatment (655 to
nintedanib plus docetaxel [322 with adenocarcinoma]
and 659 to placebo plus docetaxel [336 with adenocarci-
noma]) [16]. Patient demographics and baseline clinicalNintedanib plus docetaxel
Placebo plus docetaxel
EORTC QLQ-C30=European Organisation for Research and T
EOT=end of treatment; Sc=screening.
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Table 1
Time to deterioration of patient-reported global health status/QoL and sy
Overall
population
Adeno
popula
Global health status/QoL 0.95 (0.83–1.10) 0.86 (0
Prespeciﬁed lung cancer-speciﬁc symptoms of interest
Cough 0.90 (0.77–1.05) 0.97 (0
Dyspnoea 1.05 (0.91–1.20) 1.04 (0
Pain 0.95 (0.82–1.09) 0.93 (0
CI = conﬁdence interval; QoL = quality of life.
* Number <1 indicates beneﬁt with nintedanib; number >1 indicates bencharacteristics were well balanced across the treatment
arms for both the overall population and the prespeci-
ﬁed population of patients with adenocarcinoma [16].
More than 80% of patients included in the overall
population completed the EORTC QLQ-C30/LC13
and EQ-5D over the ﬁrst 10 courses of study treatment
with comparable proportions of responders between the
two treatment arms (Fig. 1). Approximately 70% of
patients completed the QLQ-C30 at the EOT visit. Sim-
ilar numbers of responses were also achieved for patients
with adenocarcinoma.
3.2. Baseline patient-reported outcomes
In the overall population, mean global health status/
QoL at baseline was relatively high, indicating reason-
able levels of QoL, with comparable scores for thereatment of Cancer Core Quality of Life Questionnaire, 30 items; 
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TOE8765 9 10 20
337
280
307
248
240
178
223
161
637
643
170
117
150
103
26
25
docetaxel Placebo plus docetaxel
C QLQ-C30 in overall population.
mptom scales/items.
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Patients with adenocarcinoma and
time since start of ﬁrst-line therapy <9 months
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.76–1.14) 0.80 (0.61–1.04)
eﬁt with placebo.
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Fig. 2. Kaplan–Meier curves for time to deterioration of (A) cough, (B) dyspnoea and (C) pain in the adenocarcinoma population.
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Table 2
Time to deterioration of individual EORTC QLQ-C30 and QLQ-LC13
items for the adenocarcinoma population.
Item Hazard ratio* (95%
CI)
p-Value
EORTC QLQ-C30
Q1. Trouble with strenuous
activities
0.83 (0.67–1.03) NS
Q2. Trouble taking a long walk 0.95 (0.77–1.17) NS
Q3. Trouble taking a short walk 0.92 (0.74–1.14) NS
Q4. Need to stay in bed 0.88 (0.71–1.08) NS
322 S. Novello et al. / European Journal of Cancer 51 (2015) 317–326nintedanib versus placebo groups (mean score 61.2
[standard deviation (SD) 19.9] versus 62.3 [SD 19.9]).
Baseline scores for the prespeciﬁed lung cancer-speciﬁc
symptoms of interest—cough (39.6 [SD 27.0] versus
35.9 [SD 26.4]), dyspnoea (29.8 [SD 20.5] versus 28.3
[SD 20.4]) and pain (27.0 [SD 26.9] versus 27.6 [SD
26.5])—were relatively low in both groups, indicating a
low to moderate perception of burden for these symp-
toms. Similar results were observed for the adenocarci-
noma population.Q5. Trouble eating/dressing 0.88 (0.70–1.15) NS
Q6. Trouble with daily activities 0.96 (0.78–1.18) NS
Q7. Trouble with leisure activities 1.07 (0.87–1.32) NS
Q8. Short of breath 1.04 (0.84–1.29) NS
Q9. Have pain 0.97 (0.78–1.20) NS
Q10. Need to rest 1.08 (0.87–1.33) NS
Q11. Insomnia 0.97 (0.78–1.20) NS
Q12. Felt weak 1.02 (0.83–1.25) NS
Q13. Appetite loss 1.13 (0.92–1.38) NS
Q14. Nauseated 1.27 (1.03–1.57) 0.0262
Q15. Vomited 1.42 (1.11–1.81) 0.0047
Q16. Constipation 0.89 (0.70–1.13) NS
Q17. Diarrhoea 1.86 (1.51–2.29) <0.0001
Q18. Tired 0.97 (0.79–1.19) NS
Q19. Pain aﬀecting daily activities 0.94 (0.76–1.17) NS
Q20. Trouble concentrating 1.08 (0.86–1.35) NS
Q21. Felt tense 1.11 (0.89–1.38) NS
Q22. Worried 1.03 (0.82–1.28) NS
Q23. Irritable 1.04 (0.84–1.29) NS3.3. Patient-reported outcomes for the overall population
There was no diﬀerence in TTD for cough, dyspnoea
or pain between the two treatment arms in the overall
population (Table 1). Patients’ global health status/
QoL was also maintained with nintedanib relative to
placebo (Table 1). TTD for gastrointestinal (GI) symp-
toms of diarrhoea (HR 1.94, 95% CI: 1.67–2.26),
decreased appetite (HR 1.17, 95% CI: 1.01–1.35) and
nausea and vomiting (HR 1.27, 95% CI: 1.09–1.47) were
all signiﬁcantly shorter in the nintedanib arm compared
with placebo, reﬂecting a greater incidence of these GI
adverse events with nintedanib compared with placebo,
as previously reported [16].Q24. Depressed 1.00 (0.80–1.25) NS
Q25. Trouble remembering 1.08 (0.86–1.35) NS
Q26. Family life aﬀected 1.05 (0.85–1.30) NS
Q27. Social life aﬀected 1.02 (0.82–1.26) NS
Q28. Financial diﬃculties 1.07 (0.84–1.35) NS
Q29. Overall health rating 0.92 (0.76–1.12) NS
Q30. Quality of life rating 0.82 (0.68–1.00) 0.0470
EORTC QLQ-LC13
Q1. Coughing 0.97 (0.78–1.20) NS
Q2. Haemoptysis 0.88 (0.66–1.16) NS
Q3. Dyspnoea (rested) 0.92 (0.73–1.15) NS
Q4. Dyspnoea (walked) 0.97 (0.79–1.20) NS
Q5. Dyspnoea (climbed stairs) 1.02 (0.82–1.26) NS
Q6. Sore mouth 1.04 (0.82–1.31) NS
Q7. Dysphagia 0.92 (0.72–1.17) NS
Q8. Peripheral neuropathy 1.06 (0.85–1.31) NS
Q9. Alopecia 0.85 (0.71–1.03) NS
Q10. Pain in chest 1.05 (0.84–1.30) NS
Q11. Pain in arm or shoulder 0.79 (0.63–1.00) 0.0470
Q12. Pain in other part 0.84 (0.67–1.06) NS
CI = conﬁdence interval; EORTC = European Organisation for
Research and Treatment of Cancer; QLQ-C30 = Core Quality of Life
Questionnaire, 30 items; LC13 = Lung cancer module, 13 items;
NS = not signiﬁcant.
* Number <1 indicates beneﬁt with nintedanib; number >1 indicates
beneﬁt with placebo.
 Question 13, an optional question regarding concomitant medica-
tion, was not analysed.3.4. Patient-reported outcomes for patients with
adenocarcinoma
Consistent with ﬁndings in the overall population,
TTD of cough, dyspnoea or pain for patients with ade-
nocarcinoma showed no diﬀerence between the two
treatment arms (Table 1 and Fig. 2A–C). A similar pat-
tern was observed for adenocarcinoma patients with a
duration since start of ﬁrst-line therapy <9 months
(Table 1). There was a small numerical diﬀerence in
TTD of global health status/QoL in favour of ninteda-
nib over placebo, but it did not reach statistical signiﬁ-
cance (Table 1).
There were few signiﬁcant diﬀerences between the
treatment groups for the TTD of individual QLQ-C30
or QLQ-LC13 questions (Table 2). TTD of ‘pain in
arm or shoulder’ and ‘quality of life rating’ were signif-
icantly longer with nintedanib versus placebo (Table 2).
TTD for items corresponding to the GI symptoms of
diarrhoea, decreased appetite and nausea and vomiting
were all signiﬁcantly shorter with nintedanib versus pla-
cebo (Table 2).
Longitudinal analysis of symptom scores and sub-
scores for the three key lung cancer symptoms (cough,
dyspnoea and pain) showed an overall trend towards
improvement with nintedanib in patients with adenocar-
cinoma compared with placebo (Fig. 3A). Although sta-
tistical signiﬁcance was not achieved, nintedanib-treated
patients achieved numerically lower scores than pla-
cebo-treated patients for both cough (mean diﬀerence:–0.99 [–3.44, 1.46]; p = 0.43) and pain (mean diﬀerence:
–2.13 [–4.51, 0.24]; p = 0.08), with signiﬁcant diﬀerences
observed relative to placebo for three of the individual
pain items (have pain [QLQ-C30 Q9], pain in chest
[QLQ-LC13 Q10] and pain in arm and shoulder
AB
Fig. 3. Longitudinal model estimates of diﬀerences in (A) symptom scores for cough, dyspnoea and pain and (B) function scores for the
adenocarcinoma population.
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between the two treatments was observed for dyspnoea
scores (mean diﬀerence: –0.03 [–2.00, 1.94]; p = 0.98).
Longitudinal analysis of global health status/QoL and
functional scales showed no signiﬁcant diﬀerence,
although there were numerical diﬀerences in emotional,
physical and role functioning favouring the nintedanib
group (Fig. 3B).
For the adenocarcinoma population, there was no
statistically signiﬁcant diﬀerence in EQ-5D (Fig. 4A)
or EQ-VAS (Fig. 4B) between the two treatment arms;
similar results were seen for adenocarcinoma patients
who had received ﬁrst-line therapy <9 months previ-
ously. Means calculated from AUC scores over time
also showed no statistical diﬀerence. Estimated eﬀects
of disease progression on EQ-5D utilities and changes
in EQ-VAS scores revealed that progression wasassociated with statistically highly signiﬁcant deteriora-
tion in utility (p < 0.0001).
3.5. Missing data
Missingness of PRO assessments was weakly corre-
lated to randomised treatment (because of earlier with-
drawal in the placebo group), and to baseline cough
and dyspnoea scores. Moderate correlations (Kendall’s
tau between 0.15 and 0.25) were found between missing-
ness and pain, and between missingness and EQ-5D UK
utility scores at baseline. Moderate correlations were
also found between missingness and cough, dyspnoea
and pain as well as EQ-5D UK utility scores at EOT.
In all cases, correlations were in the direction of greater
missingness with increasing severity of symptoms/worse
utility.
AB
Fig. 4. Estimated* (A) EQ-5D UK utility scores and (B) EQ-VAS scores over time in the adenocarcinoma population.
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As reported previously [16], the LUME-Lung 1 trial
demonstrated a signiﬁcant improvement in PFS with
nintedanib plus docetaxel compared with placebo plus
docetaxel as second-line therapy in patients with
relapsed/refractory NSCLC independent of histology.
Furthermore, a signiﬁcant and clinically meaningful
improvement of 2.3 months in median OS was observed
with nintedanib plus docetaxel compared with placebo
plus docetaxel in patients with adenocarcinoma [16].
Median OS for adenocarcinoma patients was greaterthan 1 year with nintedanib plus docetaxel, and a signif-
icant improvement of 3.0 months in median OS was also
observed for adenocarcinoma patients with a poor prog-
nosis (time since start of ﬁrst-line therapy <9 months).
As already published, adverse events that were more
common with nintedanib plus docetaxel versus placebo
plus docetaxel included gastrointestinal adverse events
(i.e. diarrhoea, nausea, decreased appetite and vomiting)
and elevations in liver enzymes [16].
While extending patient survival remains a goal of
second-line treatment for NSCLC, the impact of adverse
events on patient QoL must be considered in the absence
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that the survival beneﬁts achieved with nintedanib com-
bined with docetaxel in the LUME-Lung 1 trial were not
at the expense of patient QoL. No signiﬁcant diﬀerences
in the PRO composites for cough, dyspnoea or pain
were observed between the treatment groups, which is
expected since the predominant eﬀect of nintedanib in
the LUME-Lung 1 trial was to stabilise disease rather
than promote tumour shrinkage [16]. However, the
addition of nintedanib to docetaxel chemotherapy pro-
vided signiﬁcant beneﬁt in some aspects of pain relative
to placebo. In the nintedanib plus docetaxel-treated
group, there were trends towards improvements in
TTD for global health status/QoL in the adenocarci-
noma population, and for pain in adenocarcinoma
patients with a time since start of ﬁrst-line therapy
<9 months compared with the placebo plus docetaxel-
treated group. PRO scores for nausea and vomiting,
appetite loss and diarrhoea reﬂected the adverse event
proﬁle of nintedanib in the LUME-Lung 1 trial, show-
ing a greater deterioration in patients who received nint-
edanib plus docetaxel than in those who received
placebo plus docetaxel. However, the comparable global
health status/QoL between the groups demonstrates
that these GI events with nintedanib did not impair
patients’ overall health-related QoL.
The absence of deterioration in QoL in the LUME-
Lung 1 trial is consistent with the results of other
studies of second-line treatment of NSCLC. A recent
systematic review of the impact of second-line agents
on health-related QoL in NSCLC revealed that the
majority of studies reported no signiﬁcant diﬀerence
in overall QoL between treatment groups [17]. Statisti-
cally signiﬁcant improvements in overall QoL, domain/
symptom QoL, and QoL over time were more frequent
in single-arm studies and in studies that included a
treatment arm with a less toxic regimen (e.g. mono-
therapy or regimens with lower intensity). Impairment
in QoL due to adverse events related to docetaxel,
which was included in both treatment arms of the
LUME-Lung 1 study, is likely to have overwhelmed
any diﬀerences in QoL associated with nintedanib
versus placebo in this analysis. Nevertheless, it is reas-
suring to note that there was no signiﬁcant deleterious
eﬀect on overall QoL with the addition of nintedanib
to docetaxel.
Interpretation of the results reported here should
consider the strengths and limitations of the analysis.
The study protocol prespeciﬁed analyses of PROs, and
the EORTC QLQ-C30 and QLQ-LC13 instruments
used in this study are well validated for the accurate
assessment of health-related QoL in patients with lung
cancer. Furthermore, high rates of questionnaire com-
pletion were achieved throughout the study. Missing
data did show a moderate correlation with lung-cancer
speciﬁc symptoms and QoL utilities indicating apotential for bias. However, sensitivity analyses con-
ducted for PROs of global health status/QoL, cough,
dyspnoea, pain and EQ-5D UK utility showed that the
longitudinal model was relatively insensitive to alterna-
tive assumptions for data missingness (data not shown),
indicating that missing responses did not aﬀect data
interpretation.
In conclusion, the signiﬁcant improvement in PFS in
the overall population and the signiﬁcant survival bene-
ﬁt in patients with adenocarcinoma observed with the
addition of nintedanib to docetaxel therapy had no det-
rimental eﬀect on patient-reported QoL relative to the
addition of placebo. Thus, the combination of ninteda-
nib and docetaxel represents an attractive second-line
treatment option for patients with relapsed/refractory
NSCLC, and in particular for patients with adenocarci-
noma histology.Funding
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